Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

The “Frontier Pharma - Breast Cancer - Identifying and Commercializing First-in-Class Innovation” report states that breast cancer has the largest drug pipeline in the pharmaceutical industry, with 816 products in active development across all stages. Of these treatments, Publisher has identified 245 first-in-class programs acting on 175 first-in-class molecular targets, accounting for 39% of all products with a disclosed molecular target.